Disease · MONDO_0016259

carcinosarcoma of the corpus uteri

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. carcinosarcoma of the corpus uteri. Diseases, record MONDO_0016259. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016259

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: carcinosarcoma of the corpus uteri; Open Targets
Open Targets ID: MONDO_0016259; Open Targets
Other names: body of uterus carcinosarcoma, carcinosarcoma of corpus uteri, carcinosarcoma of the uterine body, carcinosarcoma of the uterine corpus, carcinosarcoma of uterine body, carcinosarcoma of uterine corpus, carcinosarcoma of uterus, corpus uteri malignant mixed mesodermal tumor, corpus uteri malignant mixed mesodermal tumour, malignant mixed Mullerian tumor of the corpus uteri, malignant mixed Mullerian tumour of the corpus uteri, malignant mixed Müllerian tumor of the corpus uteri, malignant mixed Müllerian tumour of the corpus uteri, malignant mixed mesodermal neoplasm of the uterine body, malignant mixed mesodermal neoplasm of the uterine corpus, malignant mixed mesodermal neoplasm of the uterus, malignant mixed mesodermal neoplasm of uterine body, malignant mixed mesodermal neoplasm of uterine corpus, malignant mixed mesodermal neoplasm of uterus, malignant mixed mesodermal tumor of the uterine body, malignant mixed mesodermal tumor of the uterine corpus, malignant mixed mesodermal tumor of the uterus, malignant mixed mesodermal tumor of uterine body, malignant mixed mesodermal tumor of uterine corpus, malignant mixed mesodermal tumor of uterus, malignant mixed mesodermal tumour of the uterine body, malignant mixed mesodermal tumour of the uterine corpus, malignant mixed mesodermal tumour of the uterus, malignant mixed mesodermal tumour of uterine body, malignant mixed mesodermal tumour of uterine corpus, malignant mixed mesodermal tumour of uterus, mixed Mullerian cancer of corpus uteri, mixed Mullerian sarcoma of the uterus, mixed Mullerian sarcoma of uterus, mixed Müllerian cancer of corpus uteri, mixed Müllerian sarcoma of the uterus, mixed Müllerian sarcoma of uterus, uterine body carcinosarcoma, uterine body malignant mixed mesodermal neoplasm, uterine body malignant mixed mesodermal tumor, uterine body malignant mixed mesodermal tumour, uterine corpus carcinosarcoma, uterine corpus malignant mixed Mullerian neoplasm, uterine corpus malignant mixed Mullerian tumor, uterine corpus malignant mixed Mullerian tumour, uterine corpus malignant mixed Müllerian neoplasm, uterine corpus malignant mixed Müllerian tumor, uterine corpus malignant mixed Müllerian tumour, uterine corpus malignant mixed mesodermal (Mullerian) tumor, uterine corpus malignant mixed mesodermal (Mullerian) tumour, uterine corpus malignant mixed mesodermal (Müllerian) tumor, uterine corpus malignant mixed mesodermal (Müllerian) tumour, uterine corpus malignant mixed mesodermal neoplasm, uterine corpus malignant mixed mesodermal tumor, uterine corpus malignant mixed mesodermal tumour, uterine malignant mixed mesodermal neoplasm, uterine malignant mixed mesodermal tumor, uterine malignant mixed mesodermal tumour, uterine mixed Mullerian sarcoma, uterine mixed Müllerian sarcoma; Open Targets
NCI Thesaurus: C9180; NCI Thesaurus
Orphanet: ORPHA:213610; Orphanet
Highest stage of its drugs: Phase 2, for 9 of its 10 drugs, from ClinicalTrials.gov; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IXABEPILONE	CHEMBL1201752	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PAZOPANIB HYDROCHLORIDE	CHEMBL1201733	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
THALIDOMIDE	CHEMBL468	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TOPOTECAN HYDROCHLORIDE	CHEMBL1607	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
GALUNISERTIB	CHEMBL2364611	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets36

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 36

See all 36 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00025506	Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus	Phase 2	55	2015-05-27	Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma	THALIDOMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01168232	Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer	Phase 2	42	2017-01-23	Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma	IXABEPILONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03206177	Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary	Phase 1	26	2024-08-07	Carcinosarcoma, Ovarian	CARBOPLATIN, GALUNISERTIB, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT01247571	Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer	Phase 2	22	2017-07-27	Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma	PAZOPANIB HYDROCHLORIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03951415	Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer	Phase 2	55		Endometrial Neoplasms, Uterine Neoplasms, Endometrium Cancer	DURVALUMAB, OLAPARIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00505492	Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy	Phase 2	4		Uterine Neoplasms	CARBOPLATIN, CISPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00003156	Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus	Phase 2			Sarcoma	TOPOTECAN HYDROCHLORIDE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
15975641	RESULT	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016259

GET https://conductscience.org/api/diseases/v1/MONDO_0016259/targets?page=2

API reference For AI assistants